

In Vitro Diagnostic Tests for Predicting New Cardiovascular Events

Tech ID: 19635 / UC Case 2007-261-0

TECHNOLOGY DESCRIPTION

This invention demonstrates that by measuring the OxPL/apo-B levels and Lp-PLA2 mass (or activity) one obtains complementary and synergistic information with a significant increase in the "hazard ratio" for predicting new cardiovascular events. In addition, if you measure the lipoprotein (a) and the Lp-PLA2 mass, and analyze the data together you get similar information. Therefore, by doing these combined measurements simultaneously, you can determine a higher risk if new cardiovascular events. When a patient presents to a physician, the physician would order both an OxPL/apo-B level (and or Lp(a)) and an Lp-PLA2 mass.

APPLICATIONS

Using an algorithm, the markedly improved risk prediction can be determined. Also, the invention describes a novel high-throughput assay to measure Lp-PLA2 on isolated Lp(a) particles or isolated apoB particles. Currently, the technique to detect Lp-PLA2 is done in plasma. This invention proposes to have a plate assay to capture Lp-PLA2 using specific antibodies to measure the particles. It is the use of the assay to detect Lp-PLA2 that is unique; the assay has been developed but has not yet been clinically evaluated.

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	7,939,287	05/10/2011	2007-261

CONTACT

University of California, San Diego
Office of Innovation and
Commercialization
innovation@ucsd.edu
tel: 858.534.5815.



OTHER INFORMATION

CATEGORIZED AS

- **Medical**
- Diagnostics
- Disease: Cardiovascular and Circulatory System

RELATED CASES

2007-261-0

University of California, San Diego
Office of Innovation and Commercialization
9500 Gilman Drive, MC 0910, ,
La Jolla, CA 92093-0910

Tel: 858.534.5815
innovation@ucsd.edu
<https://innovation.ucsd.edu>
Fax: 858.534.7345

© 2010 - 2011, The Regents
of the University of
California
[Terms of use](#)
[Privacy Notice](#)